Rapt Therapeutics

FCPM III Services B.V. acquired 1,489,096 RAPT Therapeutics shares in Q4, an estimated $46.24 million purchase based on quarterly average pricing that rose to $53.22 million by quarter-end. Shortly after the position was built, GSK agreed to acquire RAPT for $58 per share, roughly a 90% premium to the quarter's average purchase price, turning the holding into near-immediate gains. The trade reflects conviction in RAPT's clinical-stage assets—not deal certainty—and was effectively converted into takeout arbitrage when the acquisition closed. » More on finance.yahoo.com

OrbiMed Advisors bought 556,273 shares of RAPT Therapeutics during the quarter, raising its holding to 1,642,891 shares valued at about $55.64 million at quarter-end. Less than three weeks later RAPT was acquired by GSK for $58 per share, making OrbiMed’s purchase timely and delivering a substantial premium to the prior quarter-end price. The position represented roughly 1.1% of OrbiMed’s reportable AUM and remained a targeted biotech stake within a portfolio led by larger holdings. » More on finance.yahoo.com

RAPT Therapeutics shares rose to a 52-week high of $57.98, up 565% over the past year, with a market capitalization of $1.79 billion. InvestingPro notes a strong performance (397% in six months) but rates the stock as overbought and overvalued. GSK announced a definitive takeover agreement worth $2.2 billion, including a net upfront payment of $1.9 billion, securing worldwide rights to Ozureprubart (Phase IIb). Several analysts adjusted ratings: Leerink downgraded to market perform, while Piper Sandler and TD Cowen remain bullish. » More on de.investing.com